ANNX Live signals | Maximize Profits with Getagraph.com

BUY 101813 min ago

@ $5.26

Issued: 14 Feb 2024 @ 14:48

Return: -15.32%

Previous signal: Feb 14 - 09:31

Previous signal: Sell

Return: 2.24 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Today's Volume	3.33M
Average Volume	1.58M
Market Cap	467.63M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-0.440 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.51
ATR14	$0.0100 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock
2024-02-16	Artis Dean Richard	Buy	160 000	Stock Option (Right to Buy)

INSIDER POWER
80.78
Last 94 transactions
Buy: 9 088 380 \| Sell: 879 119

Volume Correlation

Long: -0.11 (neutral)

Short: -0.81 (strong negative)

Signal:(38.204) Neutral

Annexon, Inc. Correlation

10 Most Positive Correlations
RMRM	0.934
GTHX	0.93
STKL	0.913
NUTX	0.91
EYE	0.91
DXCM	0.91
SDG	0.909
EAR	0.908
SVOK	0.907
RRGB	0.906

10 Most Negative Correlations
HDSN	-0.916
LCA	-0.9
MDWT	-0.896
NVCN	-0.89
SENEA	-0.885
OHAA	-0.882
HNRG	-0.879
ROKU	-0.878
IGTA	-0.877
FCBP	-0.877

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Annexon, Inc. Correlation - Currency/Commodity

-0.69
( moderate negative )

0.46
( neutral )

0.00
( neutral )

-0.71
( moderate negative )

0.70
( moderate )

0.42
( neutral )

Annexon, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.27M (0.00 %)
EPS:	$-1.770

Q4	2023
Revenue:	$0
Gross Profit:	$-834 000 (0.00 %)
EPS:	$-0.360

Q3	2023
Revenue:	$0
Gross Profit:	$-823 000 (0.00 %)
EPS:	$-0.430

Q2	2023
Revenue:	$0
Gross Profit:	$-810 000 (0.00 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.